Drug Trial Radar · NCT07595393
A Dose-Finding Study of Amogammadex Sodium for Reversing Vecuronium and Rocuronium-Induced Neuromuscular Blockade
Last checked: Nov 20, 2026Latest source record: May 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
64
Planned (sponsor's estimate)
Start
Aug 1, 2026
Primary completion
Jun 30, 2027
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- Amckaus PTY LTD.Industry
- Sponsor type
- Industry
- Collaborators
- Novotech (Australia) Pty Limited
- First posted
- May 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Background context: Amogammadex sodium has completed Phase I-III clinical studies in China for reversal of rocuronium-induced blockade. No clinical studies have yet been conducted for vecuronium-induced blockade. Therefore, this dose-finding study in an Australian population is intended to support further Phase III trials in European and American populations for reversal of both rocuronium- and vecuronium-induced neuromuscular blockade. The goal of this clinical trial is to explore how well different doses of amogammadex sodium work to reverse neuromuscular blockade caused by rocuronium or vecuronium during surgery, and to learn about its safety. The main questions it aims to answer are: * How quickly and effectively does amogammadex sodium restore muscle strength after moderate or deep neuromuscular blockade? * What medical problems do participants have when receiving amogammadex sodium? Researchers will compare different doses of amogammadex sodium to see which works best. All participants will receive amogammadex sodium, but at different dose levels depending on when they join the study. Participants will: * Undergo screening up to 28 days before surgery to confirm eligibility * Receive amogammadex sodium at the end of surgery to reverse the effects of the muscle relaxant * Stay in the study for follow-up visits up to 7 days after surgery.
Conditions
- Reversing Vecuronium-Induced Neuromuscular Blockade in Patients Undergoing General Anesthesia Surgery
- Reversing Rocuronium-Induced Neuromuscular Blockade in Patients Undergoing General Anesthesia Surgery
Interventions
Rocuronium (0.6mg/kg)Drug
a single-dose intravenous bolus of 0.6 mg/kg rocuronium bromide,additional 0.1-0.2 mg/kg can be provided based on the required depth of neuromuscular blockade for surgery.
vecuronium bromide (0.1mg/kg)Drug
A single-dose intravenous bolus of 0.10 mg/kg vecuronium bromide, additional 0.015 mg/kg can be provided based on the required depth of neuromuscular blockade for surgery.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy Evaluation: The time from the start of the administration of amogammadex sodium to the recovery of the TOFr to 0.9 on day 1.Time frame: Time from the start of the administration of IP to the recovery of the TOFr to 0.9 on day 1
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.